As of Monday 3rd February 2014, all Ipsen products will be distributed via AAH Pharmaceuticals Ltd. Decapeptyl® SR (triptorelin) will be available via AAH and Phoenix/PSUK. Please click this link for more information.
About Ipsen Limited
Ipsen Limited is the UK subsidiary of Ipsen, a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2012. Ipsen's ambition is to become a global leader in the treatment of targeted debilitating diseases with a development strategy supported by three franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. Research and Development is focused on innovative patient-driven programmes in the areas of peptides and toxins. In 2012, R&D expenditure totalled more than €250 million, greater than 20% of Group sales. The Group has a total worldwide staff of close to 4,900 employees.

Information on clinical trials can be found at